Trastuzumab is directed against: (A) Human epidermal growth factor receptor 2, (B) Vascular endothelial growth factor A, (C) Platelet derived growth factor, (D) Fibroblast growth factor 23
Answer is A. Trastuzumab is a humanized monoclonal antibody directed against the extracellular domain of the (human epidermal growth factor receptor -2) HER-2 surface receptor and is effective treatment for HER-2-positive breast cancer Ref: Sabiston 20e, page: 840